Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlinkTM technology, the first ADCs are addressing molecular targets for which ADCs have already shown at least clinical promises.

Mablink is currently developing three ADC programs:

Discovery

Preclinical

Phase I

Phase II

Disc.

Precl.

Ph. I

Ph. II

MBK-101

Acute Myeloid leukemia

Preclinical

MBK-102

Multiple Myeloma

Preclinical

MBK-103

Solid Tumors

Preclinical